Aksan's Venture Capital Investments Team have Advised Livzym in Its Latest Investment Round.
Written By Aksan Law Firm | 30 July 2020

We’re pleased to announce that Aksan's venture capital investments team have advised Livzym Biyoteknoloji Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi (“Livzym”)  in its latest investment round.

Livzym is the first in MENA and CIS region company to have achieved the R&D and production of industrial enzymes through worldwide recognized biotechnical methods.

Melih Aksan, Partner, VC Investments Department led the transaction with Merve Kütükçüoğlu, Associate, Yağmur Ekin Acar, Associate, Talha Şen, Associate, Özgür Aydın, Associate.

Share with: